In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...

Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were twice ...

BERLIN, OCTOBER 19, 2025 ― Patients with cancer who received mRNA-based COVID vaccines within 100 days of starting immune checkpoint therapy were ...

Phase II trial shows belzutifan effectively shrinks rare neuroendocrine tumors and improves symptoms, offering hope for ...

Event-free survival (EFS) improved by 60% and overall survival (OS) by 50% with the antibody-drug conjugate (ADC) enfortumab vedotin (Padcev) plus pembrolizumab (Keytruda) versus upfront radical ...

Researchers at the ESMO Congress said they want to confirm their findings in a prospective randomized controlled trial.

An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice ...

After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...

A multicenter Phase II clinical trial led by researchers at The University of Texas MD Anderson Cancer Center demonstrated ...

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the ...